Gibco™ Freedom™ ExpiCHO-S™ Cell Line Development Kit on a white background

Development of New, Better Cell Line Development Kit

New Freedom™ ExpiCHO-S™ kit was co-developed by ProBioGen and Thermo Fisher Scientific

Written byThermo Fisher Scientific andProBioGen
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00

Following the success of the Gibco™ Freedom™ CHO-S Cell Line Development Kit, ProBioGen and Thermo Fisher Scientific have teamed up again to develop an even better platform: the Gibco™ Freedom™ ExpiCHO-S™ Cell Line Development Kit. It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors, or prior experience in the field. Applying its strong expertise in cell line and process development, ProBioGen has substantially contributed to the performance of the Freedom ExpiCHO-S Kit.

The new kit uses Thermo Fisher's ExpiCHO-S cell line and a new powerful media platform specifically developed for it. The kit is based on a novel set of ProBioGen vectors equipped with strong promoters, selection markers, and protective elements providing expression stability. Together with a simple workflow optimized by ProBioGen, the kit provides short development time, reproducibly high titers (3-5 g/L) and high expression stability.

Interested in life sciences?

Subscribe to our free Life Sciences Newsletter.

Is the form not loading? If you use an ad blocker or browser privacy features, try turning them off and refresh the page.

By subscribing, you agree to receive email related to Lab Manager content and products. You may unsubscribe at any time.

"Generating a stable and high performing cell line is the starting point for successful pharmaceutical development. The Gibco Freedom ExpiCHO-S Kit allows seamless transition from transient to stable production reproducing previously found product modifications. Moreover, the specific ProBioGen vector composition offers flexibility not only for antibodies but in particular for a variety of novel product formats," stated Dr. Volker Sandig, ProBioGen's Chief Scientific Officer.

Loading Next Article...
Loading Next Article...

CURRENT ISSUE - May/June 2025

The Benefits, Business Case, And Planning Strategies Behind Lab Digitalization

Joining Processes And Software For a Streamlined, Quality-First Laboratory

Lab Manager May/June 2025 Cover Image